Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod in women with IBS-C or mixed IBS
NCT00142987Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of tegaserod in irritable bowel syndrome (IBS) and Irritable bowel syndrome with mixed bowel habits (IBS-M), sponsored by Novartis. Primary endpoint: Weekly assessment of patient's overall satisfaction relief at 4 weeks. Started Apr 2004; status: completed.
02
Drugs
tegaserod
03
Conditions
irritable bowel syndrome (IBS)Irritable bowel syndrome with mixed bowel habits (IBS-M)
Beyond the preview
Go deeper on NCT00142987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142987.